ライフサイエンスコーパス: short bowel syndrome

1 ransplantation in US pediatric patients with short bowel syndrome.

2 ring therapeutic adaptation in patients with short bowel syndrome.

3 parenteral nutrition-dependent subjects with short bowel syndrome.

4 using teduglutide in US adult patients with short bowel syndrome.

5 intestinal differentiation in patients with short bowel syndrome.

6 e development of new therapeutic options for short bowel syndrome.

7 ew option for the treatment of patients with short bowel syndrome.

8 ed for parenteral nutrition in patients with short bowel syndrome.

9 ful option in the treatment of many forms of short bowel syndrome.

10 se data support the use of this operation in short bowel syndrome.

11 ion with glutamine and diet in patients with short bowel syndrome.

12 a child on chronic parenteral nutrition for short bowel syndrome.

13 edure upon intestinal function in a model of short bowel syndrome.

14 l of villus hypertrophy by the creation of a short bowel syndrome.

15 nflammatory bowel disease, malnutrition, and short bowel syndrome.

16 ransplantation in the treatment of pediatric short bowel syndrome.

17 to the treatment of patients suffering from short bowel syndrome.

18 ents with irreversible intestinal failure or short bowel syndrome.

19 parenteral nutrition in human subjects with short-bowel syndrome.

20 ta on trophic factors in adult patients with short-bowel syndrome.

21 are clinically beneficial for patients with short-bowel syndrome.

22 rowth hormone, and GLP-2 in the treatment of short-bowel syndrome.

23 en with Crohn's disease and in patients with short-bowel syndrome.

24 the treatment of selected patients with the short-bowel syndrome.

25 ery young infants and in those with surgical short-bowel syndrome.

26 bsorption and diarrhea in a patient with the short-bowel syndrome.

27 tion is a feasible therapy for patients with short-bowel syndrome.

28 eatment regimen and placebo in patients with short-bowel syndrome.

29 ten necessary in certain situations, such as short-bowel syndrome.

30 nal transplantation is used in patients with short-bowel syndrome after repeated resections for Crohn

31 In patients with short bowel syndrome, an elevated pre-resection Body Mas

32 ng glucagon-like peptide 2 (GLP2) analogs in short bowel syndrome and Crohn's disease.

33 ss-sectional study of children with neonatal short bowel syndrome and intestinal failure was conducte

34 trition (PN) is lifesaving for patients with short bowel syndrome and other gastrointestinal disorder

35 lantation has become an accepted therapy for short bowel syndrome and other types of intestinal failu

36 e performed in an emaciated patient with the short-bowel syndrome and ileostomy in whom parenteral nu

37 aintestinal manifestations, permanent stoma, short bowel syndrome), and long-term complications (gast

38 celiac disease, disaccharidase deficiencies, short bowel syndrome, and Crohn disease are discussed.

39 t gastrointestinal fistula, prolonged ileus, short bowel syndrome, and for patients with IBD with sev

40 Patients with the short bowel syndrome are maintained on long-term total p

41 ate-low fat (HCLF) diet on gut adaptation in short-bowel syndrome are unclear.

42 ntrolled, crossover study in 8 patients with short-bowel syndrome (average small bowel length, 71 cm;

43 s recommended for PN-dependent patients with short-bowel syndrome before and after transplantation fo

44 nce on parenteral nutrition in patients with short bowel syndrome by promoting enterocytic proliferat

45 Teduglutide use in pediatric patients with short bowel syndrome can aid in the achievement of enter

46 ment for PN reduction in adult patients with short bowel syndrome compared with standard intestinal r

47 Patients with congenital short-bowel syndrome (CSBS) are born with a substantial

48 pplementation were reviewed in patients with short-bowel syndrome, during cancer chemotherapy and in

49 ian, especially those who have malnutrition, short bowel syndrome, enterocutaneous fistula, and/or ar

50 Adults with short bowel syndrome have a high mortality and significa

51 MP gene have been associated with congenital short bowel syndrome, implying a role for CLMP in intest

52 Diagnoses were short bowel syndrome in 12 patients (27%), intestinal en

53 cted infants with liver failure secondary to short bowel syndrome in whom complete enteral autonomy i

54 studies (MBSs) of stable adult patients with short bowel syndrome, intestinal failure (IF) and depend

55 Short bowel syndrome is a morbid product of massive smal

56 Short bowel syndrome is an acquired condition in which t

57 The standard therapy for short bowel syndrome is total parenteral nutrition, whic

58 Although fat malabsorption in the short-bowel syndrome is caused in part by decreased bile

59 Short-bowel syndrome is the malabsorptive state that fol

60 Patients with short bowel syndrome lack sufficient functional intestin

61 PRACTICE ADVICE 8: In patients with IBD and short bowel syndrome, long-term parenteral nutrition sho

62 timulation with teduglutide in patients with short bowel syndrome might be greater if the more numero

63 Short bowel syndrome occurs when a shortened intestine c

64 spective analysis of infants <12 months with short bowel syndrome referred between 2006 and 2013 (n =

65 patients with intestinal failure because of short-bowel syndrome remain controversial.

66 Short bowel syndrome remains a condition of high morbidi

67 ematurity, low birth weight, duration of PN, short bowel syndrome requiring multiple laparotomies, an

68 redisposing this child to infection included short-bowel syndrome requiring total parenteral nutritio

69 The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), congenital

70 agonists have a benefit for the treatment of short bowel syndrome (SBS) and potentially other intesti

71 an update of recent advances in the areas of short bowel syndrome (SBS) and small bowel transplantati

72 d the GLP-2 clinical development program for short bowel syndrome (SBS) are reviewed.

73 ent of chronic intestinal failure (CIF) with short bowel syndrome (SBS) as the leading cause.

74 Short bowel syndrome (SBS) can lead to intestinal failur

75 Patients with short bowel syndrome (SBS) dependent on home parenteral

76 Intestinal adaptation in short bowel syndrome (SBS) includes morphologic processe

77 Short bowel syndrome (SBS) is a rare disease that result

78 Short bowel syndrome (SBS) is a serious malabsorption di

79 Short bowel syndrome (SBS) is associated with diminished

80 rolonged survival in pediatric patients with short bowel syndrome (SBS) is now possible because of pa

81 Short bowel syndrome (SBS) leads to severe morbidity and

82 Short bowel syndrome (SBS) may induce a plethora of clin

83 ne to improve weight gain in an experimental short bowel syndrome (SBS) model in piglets.

84 a well-characterized cohort of nonmalignant short bowel syndrome (SBS) patients.

85 cantly improved the outcome of neonates with short bowel syndrome (SBS) who require parenteral nutrit

86 l of the small bowel (SRSB) in patients with short bowel syndrome (SBS) who were "permanently" depend

87 r parenteral support volume in patients with short bowel syndrome (SBS) with intestinal failure, incr

88 The main cause of intestinal failure is short bowel syndrome (SBS).

89 small bowel (SB) dilatation in children with short bowel syndrome (SBS).

90 surgical options for managing patients with short bowel syndrome (SBS).

91 an be a lethal complication in children with short bowel syndrome (SBS).

92 prove intestinal absorption in patients with short bowel syndrome (SBS).

93 ll bowel (SRSB) is proposed in patients with short-bowel syndrome (SBS) as a rehabilitative therapy,

94 financial charges incurred by patients with short-bowel syndrome (SBS).

95 ata about these indexes exist in humans with short-bowel syndrome (SBS).

96 ectiveness in parenteral nutrition-dependent short bowel syndrome subjects were used, the ICUR increa

97 ectiveness in parenteral nutrition-dependent short bowel syndrome subjects.

98 ue-engineered intestine for the treatment of short bowel syndrome, taking into account cell source, s

99 yme could represent novel targets for future short bowel syndrome therapies.

100 A 49-year-old woman with short bowel syndrome underwent multivisceral transplanta

101 Short-bowel syndrome usually results from surgical resec

102 egulation of IEL-derived KGF expression, and short bowel syndrome was associated with an up-regulatio

103 Using a preclinical murine model of short bowel syndrome, we explored the role of autophagy

104 malignancy (particularly colonic carcinoma), short bowel syndrome (where factors such as growth hormo

105 He subsequently developed short-bowel syndrome, which required him to have total p

106 ved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral sup

107 n with a long history of Crohn's disease and short-bowel syndrome who had only 2 feet of small intest

108 of IF over the last 15 years, children with short bowel syndrome with a reduction in mortality.

109 Treatment of short bowel syndrome with a reversed jejunal segment of

110 peptide 2 analogue approved in patients with short bowel syndrome with chronic intestinal failure.

111 Short bowel syndrome with intestinal failure (SBS-IF) is

112 uid and nutrient absorption in patients with short bowel syndrome with intestinal failure (SBS-IF).

113 ross-sectional study, children with neonatal short bowel syndrome with intestinal failure experienced

114 Neonatal short bowel syndrome with intestinal failure is rare, an

115 A total of 2267 children with neonatal short bowel syndrome with intestinal failure were identi

116 ole-body protein metabolism in patients with short-bowel syndrome with intestinal failure (SBS-IF) to